A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)-Reference-Cited by-同舟云学术

A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)

Published:2012-03 Issue:5 Volume:48 Page:713-720
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Sebban C.,Lefranc A.,Perrier L.,Moreau P.,Espinouse D.,Schmidt A.,Kammoun L.,Ghesquieres H.,Ferlay C.,Bay J.O.,Lissandre S.,Pérol D.,Michallet M.,Quittet P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference35 articles.

1. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma;Philip;N Engl J Med,1987

2. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin’s disease: importance of disease status at transplant;Crump;J Clin Oncol,1993

3. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma;Vose;J Clin Oncol,1993

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

5. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline;Smith;J Clin Oncol,2006

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Effectiveness and Optimal Timing of PEG-rhG-CSF After Autologous Peripheral Blood Stem Cell Transplantation: A Multicenter Experience;Indian Journal of Hematology and Blood Transfusion;2023-10-17

2. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review;BMC Health Services Research;2022-12-30

3. Letter: Commentary: Cost-Effectiveness Analysis of Encephaloduroarteriosynangiosis Surgery for Symptomatic Intracranial Atherosclerotic Disease;Neurosurgery;2022-06-07

4. Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte–Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study;Frontiers in Pharmacology;2021-10-29

5. Efficacy and cost of G-CSF derivatives for prophylaxis of febrile neutropenia in lymphoma and multiple myeloma patients underwent autologous hematopoietic stem cell transplantation;Hematology;2021-01-01